Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans

Core Insights - The 2025-2026 formula of Spikevax has shown a greater than 8-fold increase in LP.8.1-neutralizing antibodies across various age groups [1] Company Summary - Moderna, Inc. announced positive preliminary immunogenicity data for the 2025-2026 formula of Spikevax, which targets the LP.8.1 variant of SARS-CoV-2 to help prevent COVID-19 [1] - The data comes from an ongoing Phase 4 clinical trial assessing the safety, tolerability, and immunogenicity of the new formula [1] Clinical Findings - The clinical findings indicate that individuals aged 12 to 64 years with at least one underlying condition that increases the risk for severe COVID-19 outcomes, as well as all adults aged 65 and older, experienced an average of greater than 8-fold increase in neutralizing antibodies against the LP.8.1 variant [1]